Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0903 • ACR Convergence 2021
Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?
Walter Maksymowych¹, Ulrich Weber², Xenofon Baraliakos³, Pedro Machado⁴, Susanne Pedersen⁵, Joachim Sieper⁶, Stephanie Wichuk⁷, Denis Poddubnyy⁸, Martin Rudwaleit⁹, Désirée van der Heijde¹⁰, Robert Landewé¹¹, Joel Paschke¹², Mikkel Ostergaard¹³ and Robert Lambert⁷, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹²CARE Arthritis, Edmonton, AB, Canada, ¹³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: There is no international consensus on the optimal number of slices for evaluation of MRI structural lesions in the SIJ. An “all slice” method…
Abstract Number: 0930 • ACR Convergence 2021
Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Mikkel Ostergaard¹, Joseph Wu², Lara Fallon³, Sarah P Sherlock⁴, Cunshan Wang², Dona L Fleishaker², Keith S Kanik² and Walter Maksymowych⁵, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ²Pfizer Inc, Groton, CT, ³Pfizer Canada, Montréal, QC, Canada, ⁴Pfizer Inc, Cambridge, MA, ⁵Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: The Canada-Denmark (CANDEN) MRI scoring system enables detailed anatomy-based evaluation of inflammatory and structural lesions in spinal vertebral bodies and posterior elements in patients…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 0359 • ACR Convergence 2021
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Denis Poddubnyy², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, Sergio Sanz-Gomez⁷, Pedro Plazuelo-Ramos⁸ and Victoria Navarro-Compán⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
Abstract Number: 0491 • ACR Convergence 2021
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Lianne Gensler¹, Atul Deodhar², Désirée van der Heijde³, Denis Poddubnyy⁴, Alan Kivitz⁵, Maxime Dougados⁶, Natasha de Peyrecave⁷, Marga Oortgiesen⁸, Thomas Vaux⁹, Carmen Fleurinck⁷ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 0904 • ACR Convergence 2021
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Walter Maksymowych¹, Robert Lambert², Xenofon Baraliakos³, Susanne Pedersen⁴, Iris Eshed⁵, Ulrich Weber⁶, Pedro Machado⁷, Manouk de Hooge⁸, Joachim Sieper⁹, Stephanie Wichuk², Denis Poddubnyy¹⁰, Martin Rudwaleit¹¹, Robert Landewé¹², Désirée van der Heijde¹³ and Mikkel Ostergaard¹⁴, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁵Sheba Medical Center, Ramat Gan, Israel, ⁶Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: The ASAS definition of a positive MRI for inflammation in the spine (ASAS-MRI+) is intended for classification of patients as having axSpA but is…
Abstract Number: 0931 • ACR Convergence 2021
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Sang Jin Lee, Na Ri Kim and Eon Nam, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
Background/Purpose: As biologic agents including tumor necrosis factor (TNF)-α inhibitors (TNFi) have been proven to improve enormously clinical outcomes for patients with ankylosing spondylitis (AS),…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, José Correa-Fernández⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…
Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Patompong Ungprasert¹, Thanat Chaikijurajai², Karn Wijarnpreecha³ and Paul Kroner³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
Abstract Number: 0905 • ACR Convergence 2021
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Denis Poddubnyy¹, Janis Vahldiek², Lisa Adams², Torsten Diekhoff², Fabian Proft², Mikhail Protopopov², Judith Rademacher², Valeria Rios Rodriguez², Murat Torgutalp², Stefan Niehues² and Keno Bressem², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Active inflammatory changes in sacroiliac joints (SIJ) compatible with axial spondyloarthritis - axSpA (first of all, subchondral bone marrow edema – BME / osteitis)…
Abstract Number: 0933 • ACR Convergence 2021
Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?
Walter Maksymowych¹, Robert Inman², Louis Bessette³, Proton Rahman⁴, Emmanouil Rampakakis⁵, Odalis Asin-Milan⁶, Meagan Rachich⁶, Anne Marilise Marrache⁶ and Allen Lehman⁶, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University Health Network, Toronto, ON, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada
Background/Purpose: A treat-to-target (T2T) strategy has been advocated for the management of axSpA although no consensus exists as to the most appropriate target or the…
Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Nelly Ziade¹, Joe Rassi², Bassel Elzorkany³, Clementina López Medina⁴, Sherif Gamal³, Sani Hlais⁵, Maxime Dougados⁶ and Xenofon Baraliakos⁷, ¹Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Department of Orthopedic Surgery, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ³Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Department of Family Medicine, American University of Beirut/ Saint-Joseph University, Beirut, Lebanon, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…
Abstract Number: 0047 • ACR Convergence 2021
A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
Holly Rosenzweig¹, Emily Vance², Rouhin sen³, Liron Caplan⁴ and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Colorado University Anschutz Medical Campus, Denver, CO, ⁴Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA patients have irregular neutrophil responses, as…
Abstract Number: 0361 • ACR Convergence 2021
Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, David Gálvez-Ruiz⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Physical activity is an essential component in axial spondyloarthritis (axSpA) care, improving physical and mental wellbeing. This analysis aims to identify factors associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].